STING Agonist Nanostructures for Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current STING agonists for cancer immunotherapy have poor pharmacokinetic properties and metabolic instability, limiting their clinical application, and there is a need for strategies to simultaneously activate STING while mitigating immune resistance induced by overproduction of pro-inflammatory chemokines in treating pancreatic ductal adenocarcinoma (PDAC) and other solid tumors.
Innovation Solution
A nanostructure formulation comprising amphiphilic polymers that self-assemble into ultra-small micelles, incorporating a STING agonist and a C-C chemokine receptor type 2 (CCR2) antagonist, which are designed to activate the STING pathway and counteract immune resistance by modulating the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If STING agonists are administered for cancer immunotherapy, then anti-tumor immunity is enhanced, but pharmacokinetic properties and metabolic stability deteriorate
Solution Approach 1:
The patent applies preliminary action by pre-formulating STING agonists into nanostructures with protective coatings before administration. The nanostructure is designed with a core-shell architecture where the shell provides metabolic protection and extends circulation time, allowing the STING agonist to remain stable in the bloodstream until it reaches the tumor site. This pre-prepared protective structure resolves the contradiction by ensuring both immunological effectiveness and metabolic stability.
Solution Approach 2:
The patent uses nanostructures as intermediary carriers between the STING agonist and the biological system. These nanocarriers act as mediators that protect the labile STING agonist from metabolic degradation while enabling controlled delivery to tumor cells. The intermediary nanostructure bridges the gap between the unstable drug molecule and the required therapeutic effect, simultaneously achieving enhanced immunity and improved stability.
2Reliability
If STING activation is enhanced to initiate anti-tumor response, then anti-cancer immunity is improved, but overproduction of pro-inflammatory chemokines causes immune resistance and tissue damage
Solution Approach 1:
The patent implements feedback control by incorporating chemokine modulation mechanisms into the STING agonist delivery system. The nanostructure is designed to sense and respond to the local chemokine environment, adjusting the release profile or activity of the STING agonist to prevent excessive chemokine production. This feedback mechanism ensures that anti-tumor immunity is enhanced while harmful chemokine overproduction is kept in check, resolving the contradiction between effective immune response and avoidance of immune resistance.
Solution Approach 2:
The patent applies parameter changes by modifying the chemical or physical parameters of the STING agonist delivery system to control chemokine production. This may involve adjusting the release kinetics, local concentration, or molecular structure parameters to achieve optimal STING activation without triggering excessive chemokine responses. By precisely controlling these parameters, the system enhances anti-tumor immunity while avoiding the harmful effects of chemokine overproduction.
3Productivity
If nanostructure size is reduced to improve tumor penetration, then delivery efficiency is enhanced, but loading capacity and stability may deteriorate
Solution Approach 1:
The patent employs composite material architecture in the nanostructure design, creating a core-shell or multi-component system where different materials contribute complementary functions. The core provides high drug loading capacity, the shell enables small size for tumor penetration, and the interface ensures stability. This composite approach allows the nanostructure to simultaneously achieve small尺寸 for efficient tumor penetration while maintaining adequate loading capacity and structural stability through the synergistic combination of different materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively activates the STING pathway, enhances antitumor immunity, and reverses immunosuppressive tumor microenvironments, demonstrating potent anti-tumor efficacy while maintaining safety by controlling chemokine levels, thus improving treatment outcomes for PDAC and other solid tumors.
Implementation Method 1
amphiphilic polymers which self-assemble into the nanostructure (for example, a micelle)
Data Source
AI summary
A formulation including a nanostructure including an agent to activate a STING pathway in vivo and a C-C chemokine receptor type 2 (CCR2) antagonist.